JP2015516415A5 - - Google Patents

Info

Publication number

JP2015516415A5

JP2015516415A5 JP2015511415A JP2015511415A JP2015516415A5 JP 2015516415 A5 JP2015516415 A5 JP 2015516415A5 JP 2015511415 A JP2015511415 A JP 2015511415A JP 2015511415 A JP2015511415 A JP 2015511415A JP 2015516415 A5 JP2015516415 A5 JP 2015516415A5

Authority

JP

Japan

Prior art keywords

use according

heparan sulfate

chemically modified

modified heparin

heparin

Prior art date

2013-05-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 17
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 12
• 101800000989 Oxytocin Proteins 0.000 claims description 12
• 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims description 12
• 239000003795 chemical substances by application Substances 0.000 claims description 12
• 229960001723 oxytocin Drugs 0.000 claims description 12
• 208000018525 Postpartum Hemorrhage Diseases 0.000 claims description 11
• 150000003180 prostaglandins Chemical class 0.000 claims description 9
• 229960003133 ergot alkaloid Drugs 0.000 claims description 6
• 229920002971 Heparan sulfate Polymers 0.000 claims 30
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 30
• 150000004676 glycans Polymers 0.000 claims 8
• 150000004804 polysaccharides Polymers 0.000 claims 6
• 150000002016 disaccharides Chemical class 0.000 claims 4
• 230000000694 effects Effects 0.000 claims 4
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 4
• 229960002897 heparin Drugs 0.000 claims 3
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 2
• AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical class OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims 2
• 208000010238 Uterine Inertia Diseases 0.000 claims 2
• 206010046763 Uterine atony Diseases 0.000 claims 2
• 238000011374 additional therapy Methods 0.000 claims 2
• 230000002429 anti-coagulating effect Effects 0.000 claims 2
• 230000001186 cumulative effect Effects 0.000 claims 2
• 238000009826 distribution Methods 0.000 claims 2
• -1 ergot alkaloid Chemical class 0.000 claims 2
• 150000002301 glucosamine derivatives Chemical class 0.000 claims 2
• MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 2
• 229940097043 glucuronic acid Drugs 0.000 claims 2
• 229920000669 heparin Polymers 0.000 claims 2
• 239000000825 pharmaceutical preparation Substances 0.000 claims 2
• 229920001282 polysaccharide Polymers 0.000 claims 2
• 239000005017 polysaccharide Substances 0.000 claims 2
• 125000003259 prostaglandin group Chemical group 0.000 claims 2
• 238000002560 therapeutic procedure Methods 0.000 claims 2
• 230000001858 anti-Xa Effects 0.000 claims 1
• 230000003796 beauty Effects 0.000 claims 1
• 238000007385 chemical modification Methods 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000032696 parturition Effects 0.000 claims 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
• 229960003395 carboprost Drugs 0.000 description 1
• DLJKPYFALUEJCK-MRVZPHNRSA-N carboprost Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O DLJKPYFALUEJCK-MRVZPHNRSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229960005249 misoprostol Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 150000003169 prostaglandin F2α derivatives Chemical class 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 230000013948 uterine smooth muscle contraction Effects 0.000 description 1